Back to mobile site

H.C. Wainwright Reiterates Buy Rating on BioLineRx (BLRX)

May 28, 2025 6:57 AM EDT Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $26.00 price target on BioLineRx (NASDAQ: BLRX).The analyst commented: "Yesterday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login